Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial.

For the explorative endpoint, RCB TILs were significantly predictive for response with OR = 0.56 (95% CI 0.40–0.78; p 0.0007) per 10% absolute increase in TILs and posttreatment Ki67 was borderline significant with OR 0.77 (CI 0.60–1.00; p = 0.05) per 10% increase in Ki67 index.

also in 11,409 other papers